{"id":"W4282028151","doi":"10.1200/jco.2022.40.16_suppl.589","title":"Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Clinical endpoint; Anastrozole; Palbociclib; Internal medicine; Urology; Estrogen receptor; Breast cancer; Gastroenterology; Confidence interval; Phases of clinical research; Neoadjuvant therapy; Oncology; Gynecology; Cancer; Randomized controlled trial; Tamoxifen; Chemotherapy; Metastatic breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002059177,0.001676029,0.001937975,0.0005216122,0.0003294802,0.0009365045,0.001018581,0.001145677,0.005908721],"category_scores_gemma":[0.001519182,0.000735096,0.001672652,0.0005034951,0.0009131443,0.0008879881,0.0005026746,0.002732923,0.001059094],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001449709,"about_ca_system_score_gemma":0.001899067,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002005084,"about_ca_topic_score_gemma":0.007083474,"domain_scores_codex":[0.9993013,0.0003962638,0.00004114223,0.00009972761,0.00005141288,0.0001101104],"domain_scores_gemma":[0.9992234,0.0001559441,0.0001666679,0.00006936648,0.00004666857,0.0003380011],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9668989,0.008502252,0.001083559,0.0002607822,0.0007581773,0.00003082946,0.0000444375,0.0006511512,0.003611247,0.00009454107,0.001083157,0.01698098],"study_design_scores_gemma":[0.8133059,0.1775758,0.004654306,0.00003861414,0.0008758967,0.00005530639,0.00003581514,0.0006761631,0.0008233641,0.00018956,0.001743671,0.00002562966],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831651,0.002464512,0.000643736,0.0006137759,0.0002647378,0.006720386,0.002906248,0.0001164293,0.003105086],"genre_scores_gemma":[0.9831364,0.001776001,0.0019714,0.0007963916,0.0002364741,0.005495979,0.003094413,0.00004247816,0.003450484],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005908721,"threshold_uncertainty_score":0.01976669,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0776512974025615,"score_gpt":0.4460083337624238,"score_spread":0.3683570363598623,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}